Approach to enhance human antibody expression in plant cells

基于植物的高价值治疗蛋白的生产，如单克隆抗体，为哺乳动物细胞系统中的蛋白表达提供了一个有吸引力的替代方案。PlantForm公司是一家加拿大公司，支持卡尔加里大学Douglas Muench博士实验室的研究，旨在提供一种增强的蛋白质表达技术，该技术可以普遍应用于任何高价值蛋白质的表达。PlantForm最先进的产品之一是乳腺癌治疗抗体。这笔拨款将支持一个新的合作研究项目，该项目将测试一个假设，即与翻译增强子偶联的新rna结合蛋白可以特异性地提高该抗体在植物细胞系统中的表达。卡尔加里大学的Muench实验室最近从模式植物拟南芥中鉴定了序列特异性、高亲和力的rna结合蛋白（APUM23）。当与翻译增强子偶联时，APUM23有可能显著增加这种治疗性抗体的合成。该项目的成功将为plantform带来可观的收入或节省成本，并将进一步确立该公司在植物表达治疗蛋白方面的行业领导者地位。

Plant-based production of high-value therapeutic proteins, such as monoclonal antibodies, provides anattractive alternative to protein expression in mammalian cell systems. PlantForm Corporation is an establishedCanadian company that is supporting the lab of Dr. Douglas Muench at the University of Calgary on studiesaimed at delivering an enhanced protein expression technology that can be universally applied to the expressionof any high value protein of interest. One of PlantForm's most advanced products is a breast cancer therapeuticantibody. This grant will support a new collaborative research project that will test the hypothesis that a novelRNA-binding protein coupled to a translational enhancer can specifically elevate the expression of thisantibody in a plant cell system. The Muench lab at the University of Calgary has recently characterized asequence specific, high affinity RNA-binding protein (APUM23) from the model plant Arabidopsis. Whencoupled to a translational enhancer, APUM23 has the potential to significantly increase the synthesis of thistherapeutic antibody. Success with this project will result in substantial revenue generation or cost savings toPlantForm, and will further establish the company as an industry leader in plant expression of therapeuticproteins.